Loading
A phase 1/2 trial of Paclitaxel / nab-paclitaxel, Carboplatin, Bevacizumab in ovarian cancer, run by Imunon, now recruiting.
Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer is a phase 1/2 interventional study registered as NCT05739981 by Imunon, with 30 participants planned, started 2023-02-10 and due to reach its primary completion in 2027-06-30. Interventions recorded: Paclitaxel, Carboplatin, Bevacizumab, IMNN-001. Conditions listed: Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Imunon, Paclitaxel / nab-paclitaxel, Carboplatin, Ovarian cancer.
Shares Imunon, Paclitaxel / nab-paclitaxel, Carboplatin, Ovarian cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/